Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in patients with pancreatic cancer.
According to O’Reilly, there is compelling science and biology behind using immunotherapy combinations in pancreatic cancer, since single-agent checkpoint inhibitors are insufficient. Watch here . . .